U.S. markets open in 6 hours 58 minutes

BioLife Solutions, Inc. (BLFS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
35.32-0.96 (-2.65%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close36.28
Bid0.00 x 1000
Ask0.00 x 1000
Day's Range33.80 - 37.20
52 Week Range7.37 - 47.22
Avg. Volume287,850
Market Cap1.156B
Beta (5Y Monthly)1.50
PE Ratio (TTM)299.32
EPS (TTM)0.12
Earnings DateNov 05, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.21
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-56% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • BioLife Solutions Promotes Marcus Schulz to Chief Revenue Officer
    PR Newswire

    BioLife Solutions Promotes Marcus Schulz to Chief Revenue Officer

    BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction products and services for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Chief Revenue Officer. He was previously Vice President of Global Sales.

  • BioLife Solutions (BLFS) Shines Amidst the Pandemic
    Insider Monkey

    BioLife Solutions (BLFS) Shines Amidst the Pandemic

    Wasatch Advisors, an employee-owned investment manager, published its ‘Wasatch Micro Cap Value Fund’ third-quarter 2020 Investor Letter – a copy of which can be downloaded here. A return of 11.62% was recorded by the fund for the Q3 of 2020, above its Russel Microcap benchmark that returned 3.69%. You can view the fund’s top 10 […]

  • 3 Soaring MedTech Stocks That Might Lose Ground in 2021

    3 Soaring MedTech Stocks That Might Lose Ground in 2021

    Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.